论文部分内容阅读
目的 研究外周血中可溶性白细胞介素 - 2受体 (s IL - 2 R)、白细胞介素 - 6 (IL - 6 )和淋巴细胞亚群在鉴别良、恶性卵巢病变中的作用和临床意义。方法 应用 EL ISA法、间接免疫荧光法测定了患者外周血 s IL - 2 R、IL - 6和T淋巴细胞亚群。结果 (1) 17例卵巢恶性肿瘤患者入院时 s IL - 2 R明显升高 ,高达 (337.5± 15 8.13) pg/m l,显著高于对照组及卵巢良性病变者 (P<0 .0 0 1)。 IL - 6浓度变化主要见于卵巢癌患者 (P<0 .0 1) ,并与临床预后相关 ;(2 )所有患者外周血 CD3+ 和 CD8+ 无明显改变 ,17例卵巢恶性肿瘤中有 13例 CD4+ 细胞显著减少 ,CD4/CD8比例明显下降 ,与对照组及良性卵巢病变相比差异显著 (P<0 .0 1) ;(3) 17例卵巢癌患者外周血 CD16和 CD5 6的表达均显著高于对照组 (P<0 .0 1)。结论 测定外周血 s IL - 2 R、IL - 6浓度 ,联合 T淋巴细胞亚群分析 ,不但在一定程度上反映了患者疾病的性质 ,是一个区别良、恶性卵巢病变的有效指标 ,同时还是一个方便、敏感 ,并具有一定特异性的临床指标。
Objective To investigate the role and clinical significance of sIL - 2R, IL - 6 and lymphocyte subsets in the differential diagnosis of benign and malignant ovarian lesions. Methods The levels of IL - 2R, IL - 6 and T lymphocyte subsets in peripheral blood were measured by ELISA and indirect immunofluorescence. Results (1) The levels of IL - 2 R in 17 patients with ovarian cancer were significantly higher than those in the control group and benign ovarian lesions (P <0.01 01) (337.5 ± 15 8.13 pg / ml) ). The changes of IL - 6 concentration were mainly found in ovarian cancer patients (P <0.01), and were correlated with clinical prognosis. (2) There was no significant change of CD3 + and CD8 + in peripheral blood of all patients, and 13 of 17 ovarian cancer (P <0.01). (3) The expression of CD16 and CD56 on peripheral blood of 17 patients with ovarian cancer were significantly higher than that of the control group and benign ovarian lesions Control group (P <0. 01). Conclusion The determination of sIL - 2R and IL - 6 levels in peripheral blood and the analysis of T - lymphocyte subsets not only reflect the nature of disease in patients to a certain degree, but also can be used as an effective index to differentiate benign from malignant ovarian lesions. Convenient, sensitive, and has some specific clinical indicators.